

Microbial keratitis in Southern Malawi: a microbiological pilot study

Tobi F Somerville ,¹ Shaffi Mdala,^{2,3} Thokozani Zungu,^{2,3} Moira Gandiwa,^{3,4} Rose Herbert ,¹ Dean Everett,^{5,6} Caroline E Corless,⁷ Nicholas A V Beare ,⁸ Timothy Neal,⁹ Malcolm J Horsburgh,¹⁰ Alistair Darby,¹⁰ Stephen B Kaye,¹ Petros C Kayange^{2,3}

To cite: Somerville TF, Mdala S, Zungu T, *et al.* Microbial keratitis in Southern Malawi: a microbiological pilot study. *BMJ Open Ophthalmology* 2024;**9**:e001682. doi:10.1136/bmjophth-2024-001682

► Additional supplemental material is published online only. To view, please visit the journal online (<https://doi.org/10.1136/bmjophth-2024-001682>).

Received 14 February 2024
Accepted 10 April 2024

ABSTRACT

Objective Microbial keratitis (MK) is a significant cause of blindness in sub-Saharan Africa. We investigated the feasibility of using a novel corneal impression membrane (CIM) for obtaining and processing samples by culture, PCR and whole-genome sequencing (WGS) in patients presenting with suspected MK in Malawi.

Methods and analysis Samples were collected from patients presenting with suspected MK using a 12 mm diameter polytetrafluoroethylene CIM disc. Samples were processed using culture and PCR for *Acanthamoeba*, herpes simplex virus type 1 (HSV-1) and the bacterial 16S rRNA gene. Minimum inhibitory concentrations of isolates to eight antimicrobials were measured using susceptibility strips. WGS was used to characterise *Staphylococcus aureus* isolates.

Results 71 eyes of 71 patients were included. The overall CIM isolation rate was 81.7% (58 positive samples from 71 participants). 69 (81.2%) of isolates were Gram-positive cocci. Coagulase-negative *Staphylococcus* 31.8% and *Streptococcus* species 14.1% were the most isolated bacteria. Seven (9.9%) participants were positive for HSV-1. Fungi and *Acanthamoeba* were not detected. Moxifloxacin and chloramphenicol offered the best coverage for both Gram-positive and Gram-negative isolates when susceptibility was determined using known antimicrobial first quartile concentrations and European Committee on Antimicrobial Susceptibility Testing breakpoints, respectively. WGS identified known virulence genes associated with *S. aureus* keratitis.

Conclusions In a resource-poor setting, a CIM can be used to safely sample the cornea in patients presenting with suspected MK, enabling identification of causative microorganisms by culture and PCR. Although the microbiological spectrum found was limited to the dry season, these preliminary results could be used to guide empirical treatment.

INTRODUCTION

Corneal ulceration due to microbial keratitis (MK) is recognised as one of the leading causes of blindness worldwide.¹ The incidence, prevalence and burden of disability of MK in low- and middle-income countries (LMICs) are under-reported.² The population incidence of MK in LMIC has been estimated by two studies from the tropics to range annually

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Corneal ulceration due to microbial keratitis (MK) is a significant cause of blindness in sub-Saharan Africa; however, a lack of specialised equipment and training in obtaining corneal samples means causative organisms are rarely identified and treatment is poorly targeted.

WHAT THIS STUDY ADDS

⇒ This study used a novel, simple-to-perform corneal sampling method to characterise the microbiological profile of MK in Malawi for the first time, with the causative microorganisms identified largely as Gram-positive bacteria. Preliminary susceptibility data showed moxifloxacin and chloramphenicol to offer the best antimicrobial coverage and whole-genome sequencing of *Staphylococcus aureus* isolates identified known virulence factors in MK to be present in this population.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ This study demonstrates the potential utility of the corneal impression membrane as a sampling modality in clinical practice and future research studies in Malawi and similar resource-poor settings. Although the findings are limited to the dry season in Malawi, the microbiological profile, analysis of susceptibility to commonly used ophthalmic antimicrobials and identification of virulence factors will help inform MK treatment decisions in this population.

between 113 and 362 per 100 000,^{3 4} which is at least 10 times higher than reported in North America and Europe.^{5 6}

The microbiology of MK in Malawi is unknown and clinical microbiology facilities are limited, meaning only presumptive antimicrobial treatments can be given, usually a broad-spectrum antibacterial if available. Studies from several other African countries have shown a diverse aetiology associated with MK from viral causes such as herpes simplex virus type 1 (HSV-1) to a variety of fungal and bacterial species.⁷⁻¹² There is, therefore, a need for data to enable the development



© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Dr Tobi F Somerville; tobi@liverpool.ac.uk

of strategies to reduce the burden of MK and improve outcomes in sub-Saharan Africa.

One of the main barriers to identifying the causative microorganisms has been the difficulty in collecting samples from the affected area of the cornea. The standard method requires a slit lamp biomicroscope and expertise in its use. It also requires the collection of several samples from the corneal ulcer using sharp instruments such as a scalpel blade or needle, with care taken not to inadvertently deepen the ulcer or cause additional trauma. Samples are then plated on fresh microbiological agar plates. Isolation rates using this method remain relatively poor and the specialist equipment (biomicroscope, agar plates) and personnel who can perform corneal scrapes are often not available.

We have developed a method to sample a corneal ulcer which uses a corneal impression membrane (CIM) made from polytetrafluoroethylene (PTFE) that is placed directly on the corneal ulcer.^{13 14} This method, impression cytology, has been shown to reliably remove epithelial surface cells and infective organisms, increasing the detection of bacterial,^{13 14} viral,¹⁵ fungal¹⁶ and *Acanthamoeba*¹⁷ microorganisms in cases of MK. This technique is simple to perform, less traumatic than the conventional corneal scraping method, increases the isolation and diagnostic rate^{13–15} and has been shown to promote prolonged stability and recovery of the microorganisms from samples.¹⁸ Importantly, it does not rely on using a slit lamp biomicroscopy by an ophthalmologist or suitably trained healthcare professional as the CIM is simply placed on the affected cornea for 2 s.

Samples can be transported in brain heart infusion (BHI) broth to the laboratory, where they are then plated and cultured. This does not require the direct plating of samples onto microbiological culture plates but has an equivalent isolation rate with no loss of sensitivity or specificity.¹⁹

The presence of bacterial virulence factors is an important determinant of clinical outcome, but their detection requires molecular techniques. For example, *Staphylococcus aureus* is one of the commonly isolated MK pathogens worldwide and disease outcomes are affected by the presence of virulence factors.²⁰ *S. aureus* virulence and antimicrobial resistance factors are known to differ geographically and between infections and asymptomatic carriers and information available regarding these factors in Malawi is non-existent.²¹ We, therefore, used whole-genome sequencing (WGS) to determine the presence of key virulence factors in the Malawian *S. aureus* keratitis isolates that have previously been associated with ocular *S. aureus* infection.^{22 23}

The aim of this study was to investigate the feasibility of using a CIM for obtaining and processing samples by conventional diagnostic culture, PCR and WGS in patients presenting with suspected MK in Malawi.

MATERIALS (SUBJECTS) AND METHODS

Participant recruitment

We recruited consecutive patients presenting with clinically suspected bacterial, fungal, viral or *Acanthamoeba* MK to Queen Elizabeth Central Hospital (QECH), an urban tertiary eye hospital, and Thyolo District Hospital, a rural secondary-level hospital in Malawi between April and July 2017 which is dry season. On presentation, demographic and clinical information were collected which included the type of treatment that the patient had received or was still using at presentation and risk factors such as trauma, contact lens wear, previous ocular surgery and previous MK. Best corrected visual acuity was measured using a Snellen chart and size, location and depth of the ulcer assessed using a slit lamp biomicroscope. Ulcer size (minor and major axis) and location (minimum distance from the limbus) were measured to the nearest 0.5 mm. The ulcer depth was graded on a nominal scale of 1–4 based on the proportion of corneal thickness lost on slit-lamp biomicroscopy (1: $\leq 25\%$, 2: 26%–50%, 3: 51%–75%; 4: 76%–100%).

Sample collection

Three CIM samples and two conjunctival swabs were collected from the affected eye of each patient by ophthalmic clinical officers and ophthalmology registrars who were trained in the sampling methodology. A topical anaesthetic (preservative-free oxybuprocaine 0.4%) was installed into the patient's lower conjunctival fornix. Using sterile gloves and with care to avoid contact with the eyelids or conjunctiva, a CIM (PTFE Millicell Cell Culture Insert, 12 mm, pore size of 0.4 μm ; Merck Millipore, UK) was placed over the ulcer area for 2 s. One CIM was placed immediately into BHI broth and two further CIMs were placed into empty sterile bijoux tubes. Two conjunctival swabs (Sigma Transwab and Sigma Virocult, MWE, UK) were obtained by sweeping the swab over the patient's lower fornix four times. Samples from Thyolo District Hospital were transported 40 km at room temperature by car and delivered to the Malawi-Liverpool-Wellcome Trust (MLW) laboratory within 50–60 m. Samples collected at QECH were transported to the MLW laboratory by hand, typically arriving within 5 m. On arrival at the MLW laboratory, the two dry CIMs and Virocult swab were immediately stored at -76°C . We have previously demonstrated there to be no significant reduction in microorganism DNA recovery when CIMs were stored for 3 days at temperatures up to $+35^{\circ}\text{C}$.¹⁸

Conventional diagnostic culture

The BHI bottle and transwab were vortexed for 5–10 s and 10 μL inoculated onto blood, chocolate and Sabouraud's dextrose agar plates. Blood and chocolate agar plates and the BHI broth were incubated at $35\text{--}37^{\circ}\text{C}$ and Sabouraud's dextrose agar plates were incubated at 30°C . Agar plates and a 24-hour subculture of the BHI broth were examined for evidence of bacterial growth after 24 hours and 48 hours of incubation. Sabouraud's

dextrose agar plates were examined daily for 14 days for any growth. All isolates were identified using matrix-assisted laser desorption ionization-time-of-flight mass spectrometry (Bruker, Bremen, Germany).

At a later date, bacterial minimum inhibitory concentrations (MICs) were determined for *S. aureus*, *Streptococcus* and Enterobacteriaceae isolates using susceptibility strips containing a concentration gradient of the following antimicrobials: ciprofloxacin, ofloxacin, moxifloxacin, cefuroxime, gentamicin, vancomycin, chloramphenicol and teicoplanin (BioMérieux SA, Marcy l'Etoile, France). Isolates were plated onto blood agar and incubated for 24 hours. Discrete colonies were suspended in 0.85% (w/v) saline to create an inoculum with a turbidity of 0.5 McFarland units. The inoculum was replated onto Muller-Hinton agar (*S. aureus*, Enterobacteriaceae), or Muller-Hinton agar with 5% (v/v) horse blood (*Streptococcus*), susceptibility strips applied, and plates incubated in room air or 5% carbon dioxide at 37°C. After 24 hours the e-test strips were read. The American Type Culture Collection (American Type Culture Collection, Manassas, Virginia, USA) strains 29213 (*S. aureus*), 27853 (*Pseudomonas aeruginosa*), 49619 (*Streptococcus pneumoniae*), 29212 (*Enterococcus faecalis*) and 25922 (*Escherichia coli*) were used for quality controls. Cefoxitin (30 µg) discs were used to confirm methicillin resistance in *S. aureus*. If the MIC of the antimicrobial is below the known first quartile concentration of the antimicrobial in the cornea, then it is likely that the microorganism is susceptible^{24–28} (online supplemental tables S1–S3). Bacteria were also deemed resistant if the measured MIC exceeded the breakpoint defined by the European Committee on Antimicrobial Susceptibility Testing (EUCAST).²⁹ Topical breakpoints are available for ciprofloxacin, ofloxacin and chloramphenicol; for other antibiotics, systemic breakpoints were used to determine susceptibility.

PCR

The remaining samples (two CIMs and one Virocult swab) were transported to the UK at –76°C for DNA extraction and PCR analysis. For all participants, targeted HSV-1 and *Acanthamoeba* PCR was performed. For those participants that had a negative culture, real-time 16S PCR was performed. On extraction, 400 µL of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)-based buffering agent (Hologic Aptima, Marlborough, Massachusetts, USA) was added to the CIMs and Virocult swab in their primary tubes and vortexed for 10 s. After brief centrifugation, the 400 µL of HEPES-based buffering agent was transferred to a secondary tube. DNA was selectively extracted from the decanted HEPES using the Roche MagNA Pure Compact automated extraction platform and the MagNA Pure Compact DNA isolation kit I with a final elution volume of 50 µL (Roche MagNA Pure Compact, Roche). A multiplex PCR master mix comprising of LC480 Probes Master, primers and fluorescently labelled probes (Eurogentec) for the detection of HSV-1 (Bennett *et al.*³⁰) and *Acanthamoeba* (Qvarnstrom

*et al.*³¹ and Rivière *et al.*³²) was prepared according to methods we have previously described in Somerville *et al.*¹⁸ The cycle threshold (Ct) value, which is the PCR cycle at which the emitted fluorescence reaches a defined threshold, was recorded for each reaction. Based on the work of Bennett *et al.*³⁰ and Rivière *et al.*³² a Ct value of less than or equal to 38.7 and 39.0 was set as the cut-off for a positive result for the HSV-1 and *Acanthamoeba* DNA amplification, respectively. For the detection of the bacterial 16S rRNA gene, a PCR master mix was prepared, and PCR was performed according to the methods we have previously described in Somerville *et al.*³³ Samples that were found to have a Ct value of less than or equal to 31 were amplified and sequenced according to these methods.³³

Statistical analysis was performed using SPSS (V.22). The χ^2 test was used to test associations between MK risk factors and those patients with positive isolates.

WGS of *S. aureus* keratitis isolates

The *S. aureus* keratitis isolates obtained in this study were cultured for genomic extraction by inoculating a single colony in Lysogeny broth (LB) and incubating at 37°C with shaking at 200 rpm overnight. Chromosomal DNA was extracted using the Qiagen DNeasy Blood and Tissue kit according to the manufacturer's instructions. During the cell lysis step, samples were incubated at 37°C for 30 m with 5 µL lysostaphin (stock 2.5 mg/mL DNA) and mutanolysin (1 kU/mL). The concentration and purity of genomic DNA were measured using a Qubit dsDNA high-sensitivity assay and DNA quality was visualised by agarose gel electrophoresis. Genomic DNA was barcoded using the Nanopore Native barcoding genomic DNA protocol (Version: NBE_9065_v109_revAB_14Aug2019) and sequenced on MinION (ONT, Oxford, UK) using the R9 flowcell (FLO-MIN106; ONT, Oxford, UK). Raw sequence reads were base-called and demultiplexed using ONTs minKNOW software Guppy V.4.5.4. Sequence summary and read length histograms were generated using Nanoplot³⁴ and SeqStat V.1.0.1. De novo assembly was conducted using default parameters in Canu.³⁵ To assess the virulome, BLASTx was used to query known virulence genes^{22–23} associated with ocular *S. aureus* isolates against the sequenced genomes using a 90% threshold for %identity and e-value score <0.01 (online supplemental table S4).

Patient and public involvement

Patient and public involvement informed the development of the CIM sampling method used in this study. As this was a pilot study, patients or the public were not involved in its design or conduct.

Table 1 Baseline demographics and predisposing risk factors of 71 participants presenting with presumed MK

Age (mean, SD)	39.5 years (SD 19.8)
Male participants (%)	36 (50.7%)
Participants living in a rural place of residence (%)	44 (62.0%)
Participants working in agriculture (%)	27 (38.0%)
Time between symptom onset and presentation (median, IQR)	14 days (IQR 7–38.5)
Participants referred from another health facility (%)	21 (31.0%)
HIV positive (%)	12 (17.0%)
Previous history of MK (%)	9 (12.7%)
Trichiasis (%)	9 (12.7%)
Contact lens wear (%)	0
Previous corneal surgery (%)	0
Ocular trauma (%)	11 (15.5%)
Topical antimicrobial used immediately prior to presentation (%)	29 (40.5%)
Traditional medicine use (%)	26 (36.6%)

RESULTS

Participants and ulcer characteristics

71 eyes of 71 participants with clinical suspected MK were included. Samples were obtained from 50 eyes of 50 participants recruited from QECH and 21 eyes of 21 participants from Thyolo District Hospital. The baseline demographics and predisposing risk factors are given in table 1 and the clinical characteristics of the ulcers are given in table 2. No problems were identified when transporting the CIM and swab samples from Thyolo District Hospital or QECH to the MLW laboratory.

Conventional diagnostic culture

The overall CIM isolation rate using conventional diagnostic culture was 83.0% (59 positive samples from 71 participants). This compared with 17 (23.9%) from conjunctival swabs. One further *Neisseria gonorrhoeae* was isolated from a conjunctival swab that was not isolated using a CIM.

The CIM microbial isolates are shown in table 3. Gram-positive bacteria were the predominantly isolated organisms. Coagulase-negative *Staphylococcus* (CNS) and other Gram-positive species were the most commonly isolated bacteria. No fungal growth was seen. Mixed growth was seen in 18 (25.4%) of the CIM samples

Table 2 Clinical characteristics of the ulcers of 71 participants presenting with presumed MK

Central location of ulcer (%)	53 (74.6%)
Distance from limbus (mean, SD)	2.0mm (SD 1.5)
Major diameter of ulcer (mean, SD)	4.0mm (SD 2.6)
Minor diameter of ulcer (mean, SD)	2.9mm (SD 2.6)
Mean ulcer depth grade (mean, SD)	1.0 (SD 0.9)
Corneal perforation on presentation (%)	9 (11.3%)

(table 4). CNS were found in 11/16 (68.8%) of the mixed samples with one sample having two types of CNS species present.

No association was found between ocular trauma, traditional medicine use, largest corneal ulcer diameter >5mm or corneal perforation with positive isolates (χ^2 p=0.49, 0.19, 0.32 and 0.69, respectively). All 12 patients who were HIV positive had a positive culture result (p=0.06). No significant difference was found between the isolation rate in those who had used an antimicrobial immediately prior to presentation (p=0.94).

Minimum inhibitory concentrations

MIC data were available for all but seven of the *Streptococcus* isolates which could not be recovered from storage. The MICs for each of the main bacterial subgroups are demonstrated in online supplemental tables S1–S3. The fluoroquinolones had the lowest distribution of MICs of all the antimicrobials tested for all three groups of bacteria.

Methicillin resistance was present in none of the *S. aureus* isolates (n=7). All seven *S. aureus* isolates were deemed susceptible to all antimicrobials tested using topical and systemic breakpoints determined by EUCAST²⁹ and had MICs below the reported first quartile corneal concentration for all antimicrobials tested (online supplemental table S1).

Online supplemental table S2 shows the MICs for *Streptococcus* (n=8). For the fluoroquinolones, using EUCAST breakpoints,²⁹ susceptibilities of isolates were 37.5% to ciprofloxacin, 62.5% to ofloxacin and 62.5% to moxifloxacin. All isolates had MICs below the reported first quartile corneal concentration for moxifloxacin but not for ciprofloxacin (37.5%) and ofloxacin (50%).²⁴ Using EUCAST breakpoints,²⁹ susceptibilities to the glycopeptides (eg, vancomycin) and chloramphenicol were 75%–87.5% and 100%, respectively, although 37.5% of isolates had MICs within the reported achievable aqueous humour concentrations for chloramphenicol.²⁵

Table 3 Isolates from CIMs of cases of presumed MK

	Isolates, n (%) (N=88)
Bacteria*	
Total Gram-positive	71 (80.7%)
<i>Staphylococcus aureus</i>	7 (8.0%)
<i>Streptococcus pneumoniae</i>	4 (4.5%)
Other <i>Streptococcus</i> spp†	11 (12.5%)
CNS‡	26 (29.5%)
Other Gram-positive bacteria§	23 (26.1%)
Total Gram-negative	9 (10.2)
<i>Morganella morganii</i>	3 (3.4%)
<i>Enterobacter cloacae</i>	1 (1.1%)
<i>Serratia marcescens</i>	1 (1.1%)
<i>Klebsiella variicola</i>	1 (1.1%)
<i>Citrobacter youngae</i>	1 (1.1%)
<i>Sphingomonas paucimobilis</i>	1 (1.1%)
<i>Aeromonas caviae</i>	1 (1.1%)
Fungi¶	
0	
Viral	
HSV-1**	8 (9.1%)
Protozoa	
<i>Acanthamoeba**</i>	0

*Bacterial isolates identified using culture and MALDI-TOF.

†Includes: *Streptococcus oralis* (4), *Streptococcus gordonii* (1), *Streptococcus mitis* (3), *Enterococcus faecium* (2), *Streptococcus sanguinis* (1).

‡CNS, Includes: *Staphylococcus epidermidis* (19), *Staphylococcus hominis* (3), *Staphylococcus haemolyticus* (2), *Staphylococcus nepalensis* (1), *Staphylococcus warneri* (1).

§Includes: *Bacillus* sp (5), Diphtheroid sp (7), *Micrococcus* sp (8), *Rothia mucilaginosa* (1), *Paenibacillus glucanolyticus* (1), *Kocuria marina* (1).

¶Fungal isolates identified using culture and MALDI-TOF.

**HSV-1 and *Acanthamoeba* isolates identified using targeted PCR.

CIM, corneal impression membrane; CNS, coagulase-negative *Staphylococcus*; HSV-1, herpes simplex virus type 1; MALDI-TOF, matrix-assisted laser desorption ionization-time-of-flight mass spectrometry; MK, microbial keratitis.

Online supplemental table S3 summarises the MICs for Enterobacteriaceae spp (n=6). Fluoroquinolone susceptibility using EUCAST breakpoints²⁹ was 66.7% to ciprofloxacin, 88.3% to ofloxacin and 50% to moxifloxacin. 83.5% of Enterobacteriaceae isolates had MICs below the reported first quartile corneal concentrations for each of the fluoroquinolones tested.²⁴ 83.3% of isolates were susceptible to gentamicin using the EUCAST²⁹ systemic breakpoint and all isolates had MICs below the reported first quartile corneal concentration for gentamicin.²⁶ 83.3% of Enterobacteriaceae isolates were susceptible to chloramphenicol using the EUCAST²⁹ topical breakpoint; however, all MICs were above or within the achievable reported aqueous humour concentration for chloramphenicol.

Table 4 CIM samples with more than one isolate

CIMs with five isolates	
1	<i>Serratia marcescens</i> , <i>Enterococcus faecium</i> , <i>Staphylococcus aureus</i> , <i>Corynebacterium striatum</i> , <i>Staphylococcus epidermidis</i>
CIMs with four isolates	
2	<i>Morganella morganii</i> , <i>Streptococcus gordonii</i> , <i>S. epidermidis</i> , <i>Bacillus cereus</i>
CIMs with three isolates	
3	<i>Corynebacterium pseudodiphtheriticum</i> , <i>S. epidermidis</i> , <i>Staphylococcus hominis</i>
4	<i>Klebsiella variicola</i> , <i>Enterobacter cloacae</i> , <i>Citrobacter freundii</i>
5	<i>Paenibacillus glucanolyticus</i> , <i>Kocuria marina</i> , <i>S. epidermidis</i>
6	<i>Micrococcus luteus</i> , <i>Bacillus</i> sp, HSV-1
7	<i>Streptococcus pneumoniae</i> , <i>S. epidermidis</i> , HSV-1
CIMs with two isolates	
8	<i>Staphylococcus aureus</i> , <i>Streptococcus oralis</i>
9	<i>Morganella morganii</i> , <i>S. oralis</i>
10	<i>Corynebacterium propinquum</i> , <i>S. hominis</i>
11	<i>Bacillus pumilus</i> , <i>Streptococcus mitis</i>
12	<i>Morganella morganii</i> , <i>Staphylococcus haemolyticus</i>
13	<i>Enterococcus faecium</i> , HSV-1
14	<i>S. epidermidis</i> , <i>Micrococcus luteus</i>
15	<i>S. aureus</i> , HSV-1
16	<i>Sphingomonas paucimobilis</i> , <i>S. hominis</i>
17	<i>Aeromonas caviae</i> , <i>S. epidermidis</i>
18	<i>Staphylococcus warneri</i> , <i>Micrococcus luteus</i>
CIM, corneal impression membrane; HSV-1, herpes simplex virus type 1.	

PCR results

Eight (11.3%) participants were found to have HSV-1 detected from their CIM (table 3). Four of these participants had mixed bacterial and viral infections (table 4). Of the eight participants, seven patients had a corresponding positive HSV-1 conjunctival swab. The PCR cycle threshold (Ct) result for the participant who had a positive CIM and negative conjunctival swab for HSV-1 was borderline positive (35.6). No samples tested positive for *Acanthamoeba*. For the 12 patients who had a negative culture result, 9 patients had no evidence of bacterial DNA using 16S rRNA PCR. Mixed sequences were found for all three patients who had a negative culture but detectable bacterial DNA.

WGS of Malawian *S. aureus* keratitis isolates

The baseline demographics, predisposing factors and examination findings of the seven patients that grew *S. aureus* are shown in online supplemental table S5.

Molecular classification of isolates

The core characteristics of the seven sequenced *S. aureus* isolates are presented in online supplemental table S6.

Virulence factors

Virulence genes previously associated with ocular *S. aureus* isolates or *S. aureus* keratitis^{22 23} were identified in the seven Malawian *S. aureus* keratitis isolates (online supplemental table S7). Genes encoding for adherence were found in all seven isolates with clumping factor A (*clfA*), fibronectin-binding protein A (*fnpA*) and serine-rich adhesin for platelets (*sraP*) present in all isolates. Number of evasion genes varied greatly between the isolates. The cysteine protease genes (*scpA*, *sspB* and *sspA*) were found in 100% of isolates. Staphylococcal enterotoxins were found in all but one of the isolates with varying profiles. Gamma and delta haemolysin genes were found in all seven isolates. The *lukF-PV* and *lukS-PV* gene encoding PVL were present in 3/7 (43%) and 2/7 (29%) of isolates, respectively. The methicillin resistance gene (*mecA*) was not identified in any of the seven isolates.

Of the 12 individual virulence genes proposed to be significantly enriched among *S. aureus* ocular isolates,²² *sed*, *sej*, *ser* were not found in any of the isolates, eight virulence genes (*Ψ-ent2*, *Ψ-ent1*, *seg*, *sei*, *sem*, *sen*, *seo*, *seu*) were consistently present in 5/7 (62.5%) of the isolates and one (*sev*) was present in 2/7 (29%) of the isolates. Of those virulence genes that were found to be enriched among non-ocular isolates,²² the cellular adhesion gene (*fnbB*) and cell wall surface anchor (*sraP*) were found to be present in all isolates, the superantigen *ssl8* gene in 3/7 (42.9%) isolates and the cell wall surface anchor protein (*sasG*) in 1/7 (14%) isolate (online supplemental table S6).

As the number of isolations of *S. aureus* was small, it was difficult to correlate the presence or absence of virulence factors with severity of disease due to the presence of multiple confounding host factors (presence of systemic immunosuppression, herpes zoster ophthalmicus (HZO), prior use of steroid eye drops, use of traditional medicine, etc). Two cases, case number 4 and 7, had comparatively lower numbers of evasion genes compared with the others (presence of 6 and 4 evasion genes, respectively, compared with 12–15 present in the remaining 5 cases), see online supplemental table S7. Of these, case 4 presented with a small ulcer size and good visual acuity whereas case 7 who had a background of HIV infection, HZO on presentation and who had received previous treatment with steroid eye drops presented with a much more severe MK picture. Case 5 had the highest number of virulence genes present and a severe clinical picture on presentation (visual acuity HM with a corneal ulcer measuring 6×5 mm with the presence of a hypopyon).

DISCUSSION

Clinical outcomes in MK depend on a complex interplay of host factors, microorganism virulence factors and the MIC of an antimicrobial agent against the respective microbe. Previous corneal sampling methods have relied on specialist equipment and skills. The CIM does not require specialist skills or equipment and has a higher presumed pathogen isolation rate compared with traditional scraping methods in a UK population.^{13 14} The CIM therefore, lends itself to being used in settings where such skills and equipment are unavailable.

In this study, we successfully demonstrated that the CIM could be used to obtain corneal samples and identify a possible causative microorganism using both culture and targeted PCR techniques in 83% of patients presenting with presumed MK in Malawi. We also demonstrated that it was feasible to collect such samples in a rural setting where immediate access to a microbiology laboratory was not possible.

The average time between symptom onset and presentation was longer than typically seen in the UK with ulcers being much larger on presentation (average major ulcer diameter on presentation in this study was 4 mm vs 2.14 mm seen in an average UK population).¹³ This isolation rate was higher than the 65.5% isolation rate that we demonstrated using the same CIM and sampling technique in a UK population and this is likely due to the longer presentation times, less antimicrobial use and more advanced disease on presentation.¹⁴

Due to a lack of specialist equipment, corneal samples are not routinely carried out in Malawi and therefore, the microbiological profile of MK is unknown. The CIM has previously been shown to increase isolations of presumed pathogenic microorganisms in MK compared with traditional scraping methods in a UK population^{13 14} and therefore direct comparisons between the CIM and traditional scraping methods in this population were not made. It could be argued that as the microbiological profile of MK in Malawi is unknown, the possibility that the CIM may not have detected all microorganisms that traditional corneal scrapes could have detected cannot be ruled out. That said, this study was carried out in the winter months of Malawi where the climate is typically cool and dry. Gram-positive bacteria were the most common microorganisms isolated in this population and this is consistent with other studies that have been carried out in temperate climates using traditional corneal scraping methods.³⁶

Several predisposing factors are implicated in MK which differ between countries. In this study, only 15.5% of patients had a history of previous trauma which is lower than other studies carried out in other sub-Saharan African countries.^{10 37 38} This low incidence of trauma, together with the cool and dry season that this study was undertaken in may account for the absence of fungal infections. In studies in sub-Saharan Africa (Ghana, Tanzania), that used similar fungal culture methods (Sabouraud glucose agar plates) to this study,

fungal keratitis accounts for most positive culture cases and it is therefore assumed more fungal infections would be identified in the hot and rainy season.^{12 39} The CIM has successfully identified fungal infections previously using the same sampling methodology and therefore this would not account for the fungal isolation rate in this study.¹⁴ In the future, the microbiological profile of MK in Malawi should be studied over a longer time period to better understand seasonal variability of pathogen prevalence throughout the year.

While contact lens wear is the most common risk factor in industrialised countries, trauma and ocular surface disease are more significant in low-resource settings.^{40–43} In this study, contact lens wear was non-existent and there were higher rates of trichiasis and traditional medicine use compared with other sub-Saharan MK studies.^{10 44 45} Traditional medicine use is widely practised in Malawi and can lead to damage to the ocular surface and delays in presentations to hospitals and clinics.⁴⁶ The different microorganism spectrum seen in this population with low rates of *Pseudomonas* sp infection and high rates of mixed infections compared with those seen in the UK are likely to reflect these different predisposing factors.¹⁴

The prevalence of HIV infection (17%) was higher than that reported for the general population in Malawi (10%).⁴⁷ This observation is suggestive of increased susceptibility to MK among HIV-positive individuals and is consistent with that found by Burton *et al*,¹⁰ in Tanzania. Like Burton *et al*,¹⁰ we found no association between the type of MK and HIV although previous studies have indicated that HSV-1 and fungal keratitis are more prevalent in HIV-positive patients.^{48 49} This study does emphasise the argument made by Burton *et al*¹⁰ for ophthalmologists offering MK patients referral to HIV testing services in such settings.

The percentage of CNS species and the numbers of samples obtained with more than one isolate in this study are similar to that seen using the CIM in a UK population and lead to the question of which of these are likely to be contributing to disease and which may either be contaminants or part of normal ocular flora in this population.¹⁴ The comparatively large surface area of the 12mm diameter CIM used in this study compared with the median corneal ulcer size of 4×2.9mm may favour the uptake of commensals from the patients' unaffected cornea and use of a smaller diameter CIM may reduce the culture of these bacteria. The CIM is minimally invasive and therefore can be used to obtain corneal samples from healthy eyes. Further work, taking samples from asymptomatic or unaffected eyes of patients with MK may differentiate grades of pathogenic and non-genic microorganisms and inform future treatment strategies.

In this population, we demonstrated that the detection rate for HSV-1 was higher using the CIM than the conjunctival swab and this is in keeping with our previous work that demonstrated that the CIM is more likely to detect the presence of HSV-1 in suspected herpes simplex keratitis.¹⁵

The MIC is used to determine susceptibility criteria so that an appropriate antimicrobial treatment can be chosen. Ideally, the antimicrobial with the lowest MIC and an expectation to achieve a concentration above the MIC in the cornea should be selected. If the MIC of the used antimicrobial is below the first quartile concentration of the antimicrobial in the cornea, then it is likely that the microorganism is susceptible.²⁴

The availability of antimicrobial eye drops in public health facilities in Malawi is erratic due to funding constraints. However, ciprofloxacin and gentamicin are the most available and these are the most prescribed antimicrobial agents for the treatment of MK. In this study, resistance was present to both agents in all bacterial groups other than *S. aureus*. Moxifloxacin offered the best coverage for both Gram-positive and Gram-negative isolates when susceptibility was determined using known antimicrobial first quartile concentrations whereas chloramphenicol offered the best coverage for all bacterial isolates when susceptibility was determined by EUCAST breakpoints. Although the numbers for each bacterial group are small and the results are limited to the dry season, these susceptibility data are the first of its kind to be reported on African keratitis isolates. Future research is needed to study antimicrobial resistance to topically available antimicrobials throughout the year in Malawi. It is also important to acknowledge the limitations of using in vitro sensitivity results based on systemic administration and more research is needed to study the bioavailability of antimicrobials reaching the cornea and aqueous and to establish ophthalmic breakpoints for topically applied antimicrobials.

In this study, we present the whole-genome sequences of seven Malawian *S. aureus* keratitis isolates. We observed a variety of virulence genes that have previously been associated with ocular *S. aureus* isolates or *S. aureus* keratitis.^{22 23} There are currently no studies looking at ocular *S. aureus* virulence factors in Africa to compare our data to and data concerning the virulence and pathogenesis of sub-Saharan Africa *S. aureus* clinical strains overall is limited. As the number of *S. aureus* keratitis isolates obtained in this study is small, and patients had multiple confounding host factors present, it is difficult to correlate the presence or absence of virulence factors with disease severity. Clinical outcome data were not collected as part of this study and therefore it is not possible to correlate the presence of virulence factors with clinical outcomes. Panton-Valentine leucocidin (PVL) gene expression was comparatively higher in the Malawian *S. aureus* keratitis isolates (3/7, 42.9%) than that seen in *S. aureus* keratitis isolates from the UK (9.5%).⁵⁰ PVL is associated with poorer clinical outcomes in MK⁵⁰ and is known to be high among clinical *S. aureus* strains in Africa (74% of methicillin-susceptible *S. aureus* isolates) compared with Europe (0.2%) and the USA (11.5%).^{51–54} Further investigation into the role of virulence factors in MK pathogenesis in Malawi is warranted.

In this study, we have demonstrated that the CIM sampling technique can feasibly be used to collect corneal samples from patients with suspected MK in a setting such as Malawi where access to specialist skills and equipment can be limited. Furthermore, we have demonstrated that corneal samples could feasibly be collected in rural settings where immediate access to a microbiology laboratory is not possible. Although this study is small in numbers and findings are limited to the dry season, it is the first study of its kind to characterise the microbiological profile of MK in Malawi. Results from this preliminary study support the use of the CIM in a larger study aiming to characterise the microbiological profile of MK in Malawi in a larger population over a longer time period and could also be feasibly used in other such settings to do the same. A better understanding of the causative microorganisms, microorganism susceptibilities to antimicrobials and microorganism virulence factors is greatly needed to improve patient outcomes and reduce corneal blindness in Malawi.

Author affiliations

¹Department of Eye and Vision Sciences, University of Liverpool, Liverpool, UK

²Queen Elizabeth Central Hospital, Blantyre, Southern Region, Malawi

³Ophthalmology Unit, Kamuzu University of Health Sciences, Blantyre, Southern Region, Malawi

⁴Kamuzu Central Hospital, Lilongwe, Central Region, Malawi

⁵Malawi-Liverpool-Wellcome Trust Clinical Research Programme, Blantyre, Malawi

⁶College of Medicine and Health Sciences, Infection Research Unit, Khalifa University, Abu Dhabi, UAE

⁷Medical Microbiology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK

⁸University of Liverpool, Liverpool, UK

⁹Department of Infection and Immunity, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK

¹⁰Department of Infection Biology and Microbiomes, University of Liverpool, Liverpool, UK

Acknowledgements The authors would like to acknowledge and thank the staff of QECH and Thyolo District Hospital who participated in the recruitment of patients and collection of samples and the laboratory staff at MLW who carried out culturing of samples.

Contributors TFS, NAVB, SBK and PCK devised the project and study design. The project was supervised by SBK and PCK. TFS obtained funding, sponsorship and ethical approval for the study. TN and DE developed and reviewed the culture protocol for processing samples collected in the study. CEC, MJH and AD developed and reviewed the molecular protocols for processing samples collected in the study. TFS, SM, TZ and MG were responsible for the day-to-day running of the study, recruiting study participants and collecting participant samples. DE supervised the culturing of samples at MLW. RH carried out all MIC testing. TFS carried out all molecular processing of samples and was supervised by CEC, MJH and AD. TFS analysed the data and wrote the paper with input from all authors. TFS, SBK and PCK are the guarantors of the study.

Funding This work was supported by grants from the Medical Research Council (Grant Ref: MR/S022104/1), Fight for Sight (Grant Ref: 5017 / 5018) and the British Council for Prevention of Blindness (Grant Ref: Microbial Keratitis in Malawi: A Microbiological Pilot Study).

Competing interests SBK is an editor of *BMJ Open Ophthalmology*. There are no other conflicts of interest

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval The study was approved by the College of Medicine Research Ethics Committee (COMREC, study reference: P.02/17/2116), an institutional review board (IRB) for Kamuzu University of Health Sciences and was conducted according to the ethical standards set out in the 1964 Declaration of Helsinki, as revised in 2000. Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. The data that support the findings of this study are available from the corresponding author, TS, upon reasonable request.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Tobi F Somerville <http://orcid.org/0009-0004-5662-5138>

Rose Herbert <http://orcid.org/0000-0001-6728-5125>

Nicholas A V Beare <http://orcid.org/0000-0001-8086-990X>

REFERENCES

- 1 Flaxman SR, Bourne RRA, Resnikoff S, *et al*. Global causes of blindness and distance vision impairment 1990–2020: a systematic review and meta-analysis. *Lancet Glob Health* 2017;5:e1221–34.
- 2 Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective. *Bull World Health Organ* 2001;79:214–21.
- 3 Gonzales CA, Srinivasan M, Whitcher JP, *et al*. Incidence of corneal ulceration in Madurai district, South India. *Ophthalmic Epidemiol* 1996;3:159–66.
- 4 Upadhyay MP, Karmacharya PC, Koirala S, *et al*. The Bhaktapur eye study: ocular trauma and antibiotic prophylaxis for the prevention of corneal ulceration in Nepal. *Br J Ophthalmol* 2001;85:388–92.
- 5 Erie JC, Nevitt MP, Hodge DO, *et al*. Incidence of ulcerative Keratitis in a defined population from 1950 through 1988. *Arch Ophthalmol* 1993;111:1665–71.
- 6 Seal DV, Kirkness CM, Bennett HGB, *et al*. Population-based cohort study of microbial Keratitis in Scotland: incidence and features. *Contact Lens and Anterior Eye* 1999;22:49–57.
- 7 Carmichael TR, Wolpert M, Koornhof HJ. Corneal ulceration at an urban African hospital. *Br J Ophthalmol* 1985;69:920–6.
- 8 Lewallen S, Chirambo MC. Herpetic corneal ulcers in Malawi. *Br J Ophthalmol* 1993;77:827.
- 9 Hagan M, Wright E, Newman M, *et al*. Causes of suppurative Keratitis in Ghana. *Br J Ophthalmol* 1995;79:1024–8.
- 10 Burton MJ, Pithuwa J, Okello E, *et al*. Microbial Keratitis in East Africa: why are the outcomes so poor. *Ophthalmic Epidemiol* 2011;18:158–63.
- 11 Anderson CD, Rees N, Koetsie K, *et al*. Microbial Keratitis: causative organisms, Susceptibilities and trends at a tertiary eye hospital in South Africa. *African Vision and Eye Health* 2022;81.
- 12 Leck AK, Thomas PA, Hagan M, *et al*. Aetiology of suppurative corneal ulcers in Ghana and South India, and epidemiology of fungal Keratitis. *Br J Ophthalmol* 2002;86:1211–5.
- 13 Kaye S, Sueke H, Romano V, *et al*. Impression membrane for the diagnosis of microbial Keratitis. *Br J Ophthalmol* 2016;100:607–10.
- 14 Somerville TF, Herbert R, Neal T, *et al*. An evaluation of a simplified impression membrane sampling method for the diagnosis of microbial Keratitis. *J Clin Med* 2021;10:5671.
- 15 Brunner M, Somerville T, Corless CE, *et al*. Use of a corneal impression membrane and PCR for the detection of herpes Simplex virus Type-1. *J Med Microbiol* 2019;68:1324–9.
- 16 Jain AK, Bansal R, Felcida V, *et al*. Evaluation of impression smear in the diagnosis of fungal Keratitis. *Indian J Ophthalmol* 2007;55:33–6.

- 17 Sawada Y, Yuan C, Huang AJW. Impression cytology in the diagnosis of acanthamoeba Keratitis with surface involvement. *Am J Ophthalmol* 2004;137:323–8.
- 18 Somerville TF, Corless CE, Neal T, et al. Effect of storage time and temperature on the detection of *Pseudomonas Aeruginosa*, *Acanthamoeba* and herpes Simplex virus from corneal impression membranes. *J Med Microbiol* 2018;67:1321–5.
- 19 Kaye SB, Rao PG, Smith G, et al. Simplifying collection of corneal specimens in cases of suspected bacterial Keratitis. *J Clin Microbiol* 2003;41:3192–7.
- 20 Tuft S, Somerville TF, Li J-P, et al. Bacterial Keratitis: identifying the areas of clinical uncertainty. *Prog Retin Eye Res* 2022;89:101031.
- 21 Schaumburg F, Ngoa UA, Kösters K, et al. Virulence factors and genotypes of *Staphylococcus aureus* from infection and carriage in Gabon. *Clin Microbiol Infect* 2011;17:1507–13.
- 22 Johnson WL, Sohn MB, Taffner S, et al. Genomics of *Staphylococcus aureus* ocular isolates. *PLoS One* 2021;16:e0250975.
- 23 Afzal M, Vijay AK, Stapleton F, et al. Virulence genes of *Staphylococcus aureus* associated with Keratitis, conjunctivitis, and contact lens-associated inflammation. *Transl Vis Sci Technol* 2022;11:5.
- 24 Herbert R, Caddick M, Somerville T, et al. Potential new fluoroquinolone treatments for suspected bacterial Keratitis. *BMJ Open Ophthalmol* 2022;7:e001002.
- 25 Beasley H, Boltralik JJ, Baldwin HA. Chloramphenicol in aqueous humor after topical application. *Arch Ophthalmol* 1975;93:184–5.
- 26 Eljarrat-Binstock E, Raiskup F, Stepensky D, et al. Delivery of gentamicin to the Rabbit eye by drug-loaded Hydrogel Iontophoresis. *Invest Ophthalmol Vis Sci* 2004;45:2543.
- 27 Cahane M, Ben Simon GJ, Barequet IS, et al. Human corneal Stromal tissue concentration after consecutive doses of topically applied 3.3% vancomycin. *Br J Ophthalmol* 2004;88:22–4.
- 28 Kaye SB, Neal T, Nicholson S, et al. Concentration and bioavailability of ciprofloxacin and Teicoplanin in the Cornea. *Invest Ophthalmol Vis Sci* 2009;50:3176.
- 29 European Committee on Antimicrobial Susceptibility Testing committee. Clinical breakpoints - breakpoints and guidance. 2023.
- 30 Bennett S, Carman WF, Gunson RN. The development of a multiplex real-time PCR for the detection of herpes simplex virus 1 and 2, Varizella Zoster virus, adenovirus and Chlamydia Trachomatis from eye Swabs. *J Virol Methods* 2013;189:143–7.
- 31 Qvarnstrom Y, Visvesvara GS, Sriram R, et al. Multiplex real-time PCR assay for simultaneous detection of *Acanthamoeba* Spp. *Balamuthia Mandrillaris*, and *Naegleria Fowleri*. *J Clin Microbiol* 2006;44:3589–95.
- 32 Rivière D, Szczebara FM, Berjeaud J-M, et al. Development of a real-time PCR assay for quantification of *Acanthamoeba* trophozoites and cysts. *J Microbiol Methods* 2006;64:78–83.
- 33 Somerville TF, Corless CE, Sueke H, et al. 16S Ribosomal RNA PCR versus conventional diagnostic culture in the investigation of suspected bacterial Keratitis. *Transl Vis Sci Technol* 2020;9:2.
- 34 De Coster W, Rademakers R. Nanopack2: population-scale evaluation of long-read sequencing data. *Bioinformatics* 2023;39:btad311.
- 35 Koren S, Walenz BP, Berlin K, et al. Canu: Scalable and accurate long-read assembly via adaptive K-Mer weighting and repeat separation. *Genome Res* 2017;27:722–36.
- 36 Shah A, Sachdev A, Coggon D, et al. Geographic variations in microbial Keratitis: an analysis of the peer-reviewed literature. *Br J Ophthalmol* 2011;95:762–7.
- 37 Gebremariam TT. Bacteriology and risk factors of bacterial Keratitis in Jimma, Southwest Ethiopia. *Ethiop Med J* 2015;53:191–7.
- 38 Ezegwui IR. Corneal ulcers in a tertiary hospital in Africa. *J Natl Med Assoc* 2010;102:644–6.
- 39 Poole TRG, Hunter DL, Maliwa EMK, et al. Aetiology of microbial Keratitis in northern Tanzania. *Br J Ophthalmol* 2002;86:941–2.
- 40 Bourcier T, Thomas F, Borderie V, et al. Bacterial Keratitis: predisposing factors, clinical and Microbiological review of 300 cases. *Br J Ophthalmol* 2003;87:834–8.
- 41 Dart JKG, Stapleton F, Minassian D, et al. Contact lenses and other risk factors in microbial Keratitis. *The Lancet* 1991;338:650–3.
- 42 Tewari A, Sood N, Vegad MM, et al. Epidemiological and microbiological profile of infective Keratitis in Ahmedabad. *Indian J Ophthalmol* 2012;60:267–72.
- 43 Bharathi MJ, Ramakrishnan R, Meenakshi R, et al. Microbial Keratitis in South India: influence of risk factors, climate, and geographical variation. *Ophthalmic Epidemiol* 2007;14:61–9.
- 44 Oladigbolu K, Rafindadi A, Abah E, et al. Corneal ulcers in a tertiary hospital in northern Nigeria. *Ann Afr Med* 2013;12:165–70.
- 45 Saka S, Ademola-Popola D, Mahmoud A, et al. Presentation and outcome of microbial Keratitis in Ilorin, Nigeria. *BJMMR* 2015;6:795–803.
- 46 Courtright P, Lewallen S, Kanjaloti S, et al. Traditional eye medicine use among patients with corneal disease in rural Malawi. *Br J Ophthalmol* 1994;78:810–2.
- 47 UNAIDS Data. HIV and AIDS in Malawi. 2008. Available: <https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/malawi> [Accessed 3 Aug 2022].
- 48 Schafftenaar E, Peters RPH, Baarsma GS, et al. Clinical and corneal microbial profile of infectious Keratitis in a high HIV prevalence setting in rural South Africa. *Eur J Clin Microbiol Infect Dis* 2016;35:1403–9.
- 49 Mselle J. Fungal Keratitis as an indicator of HIV infection in Africa. *Trop Doct* 1999;29:133–5.
- 50 Sueke H, Shankar J, Neal T, et al. lukSF-PV in *Staphylococcus aureus* Keratitis isolates and association with clinical outcome. *Invest Ophthalmol Vis Sci* 2013;54:3410–6.
- 51 Brown ML, O'Hara FP, Close NM, et al. Prevalence and sequence variation of Pantone-Valentine Leukocidin in Methicillin-resistant and Methicillin-susceptible *Staphylococcus aureus* strains in the United States. *J Clin Microbiol* 2012;50:86–90.
- 52 Tattevin P, Schwartz BS, Graber CJ, et al. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated Methicillin-resistant *Staphylococcus aureus*. *Clin Infect Dis* 2012;55:781–8.
- 53 Becker K, Schaumburg F, Fegeler C, et al. *Staphylococcus aureus* from the German general population is highly diverse. *Int J Med Microbiol* 2017;307:21–7.
- 54 Grebe T, Rudolf V, Gouleu CS, et al. Neutralization of the *Staphylococcus aureus* Pantone-Valentine Leukocidin by African and Caucasian sera. *BMC Microbiol* 2022;22:219.

Supplementary data

Strain	Ciprofloxacin/ Ofloxacin			Moxifloxacin			Cefuroxime			Gentamicin			Vancomycin/ Teicoplanin			Chloramphenicol		
	MIC	S ¹	S ²	MIC	S ¹	S ²	MIC	S ¹	S ²	MIC	S ¹	S ²	MIC	S ¹	S ²	MIC	S ¹	S ²
1	0.25 / 0.19	S	S	0.023	S	S	1.5	na	S	0.125	S	S	1.0 / 0.38	S	S	3.0	S	S
2	0.19 / 0.38	S	S	0.047	S	S	2.0	na	S	0.5	S	S	1.0 / 0.25	S	S	4.0	B	S
3	0.125 / 0.19	S	S	0.032	S	S	1.5	na	S	0.25	S	S	1.5 / 0.25	S	S	3.0	S	S
4	0.25 / 0.38	S	S	0.047	S	S	0.25	na	S	0.064	S	S	1.5 / 0.25	S	S	2.0	S	S
5	0.19 / 0.38	S	S	0.032	S	S	2.0	na	S	0.38	S	S	1.5 / 0.75	S	S	4.0	B	S
6	0.19 / 0.38	S	S	0.032	S	S	1.5	na	S	0.5	S	S	1.5 / 0.5	S	S	4.0	B	S
7	0.38 / 0.38	S	S	0.023	S	S	1.5	na	S	0.25	S	S	1.0 / 0.25	S	S	4.0	B	S
Total susceptible (%):	100	100		100	100		na	100		100	100		100	100				100

Data are in milligrams per litre (mg/L). S = Susceptible; R = Resistant; B = Borderline (within stated antimicrobial corneal concentration range)

S¹: Susceptibility determined using known antimicrobial 1st quartile corneal concentrations. If the MIC is below the reported 1st quarter corneal concentration for that antimicrobial, then it is reasonable to expect the bacterial to be inhibited by that antimicrobial and the strain is reported as susceptible. Although the reported corneal concentrations of antimicrobials are high, the associated standard deviations are high, meaning that the concentrations are not consistent around the mean. Because the actual data is not available in the listed references, the first quartile concentration has been extrapolated from the reported mean and standard deviation unless the median was available. Data is not available in articles to check normality. The pharmacokinetics of antimicrobials in corneal ulceration is unknown, so caution is needed in extrapolating data. Reported 1st quarter corneal concentrations for the antimicrobials are as follows: ciprofloxacin: 2.40-3.71mg/kg (24), ofloxacin: 4.73-6.79mg/kg (24), moxifloxacin: 5.11-9.62mg/kg (24), cefuroxime: no available information in the literature, gentamicin: 12.71mg/kg (only reported in rabbit eyes (33)), vancomycin: 33.1mg/kg (53), teicoplanin: 7.6mg/L (n=20, 0mg/L in 9 patients) (54); chloramphenicol: 3.5-6.7mg/kg (concentrations only available for aqueous humor and no 1st quartile concentration available (32)).

S²: Susceptibility determined by the breakpoint defined by EUCAST (25). Topical breakpoints are available for ciprofloxacin (1mg/L), ofloxacin (1mg/L) and chloramphenicol (16mg/L). For the other antimicrobials, systemic breakpoints were used: moxifloxacin (0.25mg/L), cefuroxime susceptibility was inferred from ceftioxin disc testing, gentamicin (2mg/L), teicoplanin (2mg/L) and vancomycin (2mg/L).

Strain	Ciprofloxacin/ Ofloxacin			Moxifloxacin			Cefuroxime			Gentamicin			Vancomycin/ Teicoplanin			Chloramphenicol		
	MIC	S ¹	S ²	MIC	S ¹	S ²	MIC	S ¹	S ²	MIC	S ¹	S ²	MIC	S ¹	S ²	MIC	S ¹	S ²
1	4.0 / 1.5	R / S	R / S	0.19	S	S	0.094	na	na	3.0	S	na	1.0 / 0.38	S	S	1.5	S	S
2	0.38 / 1.0	S	S	0.12 5	S	S	0.19	na	na	4.0	S	na	1.0 / 0.094	S	S	2.0	S	S
3	3.0 / 6.0	B / R	R	4.0	S	R	0.75	na	na	48	R	na	2.0 / 0.38	S	S	6.0	B	S
4	4.0 / 0.25	R / S	R / S	1.5	S	R	6.0	na	na	6.0	S	na	6.0 / 0.125	S	R / S	6.0	B	S
5	4.0 / 6.0	R	R	0.38	S	S	0.25	na	na	24	R	na	1.0 / 0.125	S	S	2.0	S	S
6*	0.25 / 0.25	S	S	0.38	S	S	3.0	na	na	1.0	S	na	256 / 256	R	R	4.0	B	S
7	6.0 / 12.0	R	R	0.5	S	S	1.0	na	na	12	B	na	0.75 / 0.047	S	S	2.0	S	S
8	1.5 / 8.0	S / R	S / R	0.75	S	R	1.0	na	na	1.5	S	na	0.75 / 0.75	S	S	1.0	S	S
Total susceptible (%)	37.5 / 50	37.5 / 50	37.5 / 62.5		100	62.5		na	na		62.5	na		87.5	75.0 / 87.5		62.5	100

Data are in milligrams per litre (mg/L). S = Susceptible; R = Resistant; B = Borderline (within stated antimicrobial corneal concentration range)

S¹: Susceptibility determined using known antimicrobial 1st quartile corneal concentrations. If the MIC is below the reported 1st quarter corneal concentration for that antimicrobial, then it is reasonable to expect the bacterial to be inhibited by that antimicrobial and the strain is reported as susceptible. Although the reported corneal concentrations of antimicrobials are high, the associated standard deviations are high, meaning that the concentrations are not consistent around the mean. Because the actual data is not available in the listed references, the first quartile concentration has been extrapolated from the reported mean and standard deviation unless the median was available. Data is not available in articles to check normality. The pharmacokinetics of antimicrobials in corneal ulceration is unknown, so caution is needed in extrapolating data. Reported 1st quarter corneal concentrations for the antimicrobials are as follows: ciprofloxacin: 2.40-3.71mg/kg (24), ofloxacin: 4.73-6.79mg/kg (24), moxifloxacin: 5.11-9.62mg/kg (24), cefuroxime: no available information in the literature, gentamicin: 12.71mg/kg (only reported in rabbit eyes (33)), vancomycin: 33.1mg/kg (53), teicoplanin: 7.6mg/L (n=20, 0mg/L in 9 patients) (54); chloramphenicol: 3.5-6.7mg/kg (concentrations only available for aqueous humor and no 1st quartile concentration available (32)).

S²: Susceptibility determined by the breakpoint defined by EUCAST (25). Topical breakpoints are available for ciprofloxacin (1mg/L), ofloxacin (1mg/L) and chloramphenicol (16mg/L). For the other antimicrobials, systemic breakpoints were used: moxifloxacin (0.25mg/L), cefuroxime susceptibility was inferred from cefoxitin disc testing, gentamicin (2mg/L), teicoplanin (2mg/L) and vancomycin (2mg/L).

Strain	Ciprofloxacin/ Ofloxacin			Moxifloxacin			Cefuroxime			Gentamicin			Vancomycin/ Teicoplanin			Chloramphenicol		
	MIC	S ¹	S ²	MIC	S ¹	S ²	MIC	S ¹	S ²	MIC	S ¹	S ²	MIC	S ¹	S ²	MIC	S ¹	S ²
1	32 / 32	R	R	32	R	R	128	na	R	6.0	S	R	256 / 256	R	na	256	R	R
2	0.008 / 0.064	S	S	0.064	S	S	96	na	R	0.75	S	S	256 / 256	R	na	4.0	B	S
3	0.004 / 0.064	S	S	0.094	S	S	12	na	R	0.38	S	S	256 / 256	R	na	8.0	R	S
4	0.19 / 0.25	S	R / S	0.75	S	R	96	na	R	2.0	S	S	256 / 256	R	na	6.0	B	S
5	0.012 / 0.125	S	S	0.125	S	S	6.0	na	S	1.0	S	S	256 / 256	R	na	4.0	B	S
6	0.016 / 0.25	S	S	0.38	S	R	3.0	na	S	0.38	S	S	256 / 256	R	na	4.0	B	S
Total susceptible (%)	83.3	66.7 / 83.3		83.3	50.0			na	33.3		100	83.3		0	na		0	83.3

Data are in milligrams per litre (mg/L). S = Susceptible; R = Resistant; B = Borderline (within stated antimicrobial corneal concentration range)

S¹: Susceptibility determined using known antimicrobial 1st quartile corneal concentrations. If the MIC is below the reported 1st quarter corneal concentration for that antimicrobial, then it is reasonable to expect the bacterial to be inhibited by that antimicrobial and the strain is reported as susceptible. Although the reported corneal concentrations of antimicrobials are high, the associated standard deviations are high, meaning that the concentrations are not consistent around the mean. Because the actual data is not available in the listed references, the first quartile concentration has been extrapolated from the reported mean and standard deviation unless the median was available. Data is not available in articles to check normality. The pharmacokinetics of antimicrobials in corneal ulceration is unknown, so caution is needed in extrapolating data. Reported 1st quarter corneal concentrations for the antimicrobials are as follows: ciprofloxacin: 2.40-3.71mg/kg (24), ofloxacin: 4.73-6.79mg/kg (24), moxifloxacin: 5.11-9.62mg/kg (24), cefuroxime: no available information in the literature, gentamicin: 12.71mg/kg (only reported in rabbit eyes (33)), vancomycin: 33.1mg/kg (53), teicoplanin: 7.6mg/L (n=20, 0mg/L in 9 patients) (54); chloramphenicol: 3.5-6.7mg/kg (concentrations only available for aqueous humor and no 1st quartile concentration available (32)).

S²: Susceptibility determined by the breakpoint defined by EUCAST (25). Topical breakpoints are available for ciprofloxacin (1mg/L), ofloxacin (1mg/L) and chloramphenicol (16mg/L). For the other antimicrobials, systemic breakpoints were used: moxifloxacin (0.25mg/L), cefuroxime susceptibility was inferred from ceftioxin disc testing, gentamicin (2mg/L), teicoplanin (2mg/L) and vancomycin (2mg/L).

Table S4: Class, gene identity, function, reference genome and GeneID of the <i>S. aureus</i> virulence factor database used in this study					
Functional class	Gene	Description	<i>S. aureus</i> reference genome	GeneID	Length
	<i>mecA</i>	Confers resistance to methicillin	7292 reference <i>Staphylococcus</i> sequences	WP_001801873.1	669 AA
Adherence	<i>clfA</i> *	Clumping factor A, fibrinogen binding protein	MW2	Q8NXJ1	946 AA
	<i>fnpA</i> * ^s	Fibronectin-binding protein A	MW2	Q8NUU7	1015 AA
	<i>eap/map</i> *	Truncated map-W protein	Mu50	BAB58100.1	476 AA
	<i>sasG</i> ^s	Cell wall surface anchor family protein	COL	A0A0H2WXE4	1243 AA
	<i>sraP</i> ^s	LPXTG Cell wall surface anchor family protein	COL	Q5HCP3	2261 AA
Evasion	<i>scpA</i> *	Cysteine protease Staphopain A	Mu50	P65825	388 AA
	<i>sspB</i> *	Cysteine proteinase Staphopain B	MW2	Q8NX99	393 AA
	<i>sspA</i> *	Glutamyl endopeptidase V8	MW2	Q8NX98.1	327 AA
	<i>coa</i> *	Staphylocoagulase precursor	N315	BAB41444.1	658 AA
	<i>seb</i> *	Staphylococcal enterotoxin B	S6	AAA88550.1	266 AA
	<i>hla/hly</i> *	Alpha-hemolysin precursor	MW2	BAB94909.1	319 AA
	ψ ent1 [#]	Enterotoxin ψ ent1	N315	BAB42913.1	133AA
	Ψ ent2 [#]	Enterotoxin Ψ ent2	N315	BAB42912.1	136 AA
	<i>selo</i> [#]	<i>Staphylococcal</i> enterotoxin O	RF122	CAI81390.1	254 AA
	<i>seln</i> [#]	<i>Staphylococcal</i> enterotoxin N	RF122	CAI81386.1	251 AA
	<i>selm</i> [#]	<i>Staphylococcal</i> enterotoxin M	N315	WP_000821658.1	239 AA
<i>sei</i> [#]	<i>Staphylococcal</i> enterotoxin I	RF122	CAI81388.1	242 AA	

	<i>seg#</i>	<i>Staphylococcal</i> enterotoxin G	RF122	CAI81385.1	205 AA
	<i>selv#</i>	<i>Staphylococcal</i> enterotoxin V	A900624	WP_043859283.1	239 AA
	<i>seu#</i>	<i>Staphylococcal</i> enterotoxin U	RF122	WP_000764692	261 AA
	<i>sed#</i>	<i>Staphylococcal</i> enterotoxin D precursor	RN4220	AAB06195.1	258 AA
	<i>sej#</i>	<i>Staphylococcal</i> enterotoxin J	2144 identical sequences	WP_000750881.1	268 AA
	<i>ser#</i>	<i>Staphylococcal</i> enterotoxin R	2018 identical sequences	WP_000932627.1	259 AA
	<i>ssl8[§]</i>	Superantigen-like protein 8	MW2	AUU67599.1	232 AA
Invasion	<i>hlgA*</i>	Gamma- hemolysin chain II precursor	MW2	BAB96207.1	309 AA
	<i>hlgB*</i>	Gamma- hemolysin component B	MW2	BAB96209.1	325 AA
	<i>hlgC*</i>	Gamma- hemolysin component C	MW2	BAB96208.1	315 AA
	<i>hld*</i>	Delta-hemolysin	MW2	BAB95824.1	44 AA
	<i>lukF-PV*</i>	Panton-Valentine leukocidin precursor chain F	MW2	BAB95243.1	325 AA
	<i>lukS*</i>	Panton-Valentine leukocidin precursor chain S	MW2	BAB95244.1	312 AA

*Virulence genes used by Afzal et al (23).

#Virulence genes associated with ocular *S. aureus* isolates (22)

§Virulence genes associated with non-ocular *S. aureus* isolates (22).

Table S5: Baseline demographics, predisposing factors and examination findings of the seven patients with MK who had <i>S. aureus</i> isolated.							
	1	2	3	4	5	6	7
Baseline demographics and predisposing factors:							
Sex	F	F	F	M	M	M	M
HIV positive	Yes	Unknown	No	Unknown	Yes	Unknown	Yes
Previous history of MK	Yes	No	No	No	No	No	No
Topical eyedrop treatment prior to presentation	No	Yes - tetracycline	No	No	No	No	Yes - dexamethasone
Traditional medicine use	no	Yes	No	No	No	No	Yes
Examination findings:							
Snellen VA on presentation	HM	6/60	6/60	6/6	HM	NM	HM
Location of ulcer	Central	Central	Peripheral	Peripheral	Central	Peripheral	Central
Major diameter of ulcer (mm)	1	NM	1	0.5	6	NM	11
Minor diameter of ulcer (mm)	1	NM	1	0.5	5	NM	11
Ulcer depth	1	1	2	1	NM	2	2
Hypopyon	No	No	No	No	Yes	No	No
Other examination findings:	-	-	-	-	HZO	-	HZO
Mixed culture growth	Yes*	Yes**	No	No	No	Yes***	No

NM: not measured.

HZO: Herpes Zoster Ophthalmicus

*Mixed growth with *Enterococcus faecium*, *Corynebacterium striatum*, *Serratia marcescens* and *S. epidermidis*

**Mixed growth with *S. oralis*.

***Mixed growth with HSV-1

	1	2	3	4	5	6	7
Total length (bp)	3,198,350	2,884,721	2,796,874	2,832,020	2,850,395	2,925,823	2,808,597
Contigs	6	1	6	2	3	1	1
Largest contig	2,932,126	2,884,721	2,369,645	2,806,382	2,800,994	2,925,823	2,808,597
N50 (bp)	2,932,126	2,884,721	2,369,645	2,806,382	2,800,994	2,925,823	2,808,597
GC (%)	32.59	32.79	32.72	32.82	32.68	32.81	32.88
Prophage Regions	5	5	2	3	2	4	3
Plasmids	3	3	4	1	4	3	0
MLST	Unknown* 59 nearest STs	?ST-34*	Unknown Nearest ST-1940 [#]	Unknown Nearest ST-4803 ^{&}	?ST-1940 [%]	Unknown [§] 8 nearest STs	?ST-152
Spa type	t1130	t136	t3772	t064	t2554	t136	t355
agr-type	III	III	I	I	I	III	I

*Imperfect hit with *aroE* (identity 99.8%, coverage 99.8%)

[#]Imperfect hit with *arcC* (identity 99.8%, coverage 99.8%) and *gmk* (identity 99.8%, coverage 99.8%)

[&]Imperfect hit with *gmk* (identity 99.5%, coverage 99.5%)

[%]Imperfect hit with *arcC* (identity 99.3%, coverage 99.3%) and *gmk* (identity 99.8%, coverage 99.8%)

[§]Imperfect hit with *arcC* (identity 99.6%, coverage 9.8%)

[^]Imperfect hit with *arcC* (identity 99.8%, coverage 99.8%), *aroE* (identity: 99.8%, coverage 99.8%) and *gmk* (identity 99.8%, coverage 99.8%)

Table S7: Presence or absence of known virulence genes associated with ocular <i>S. aureus</i> strains									
Functional class	Gene	<i>S. aureus</i> genome							Total
		1	2	3	4	5	6	7	
	<i>mecA</i>	0	0	0	0	0	0	0	0
Adherence	<i>clfA</i> *	1	1	1	1	1	1	1	7
	<i>fnpA</i> * [§]	1	1	1	1	1	1	1	7
	<i>eap/map</i> *	0	0	1	0	1	0	0	2
	<i>sasG</i> [§]	0	0	0	1	0	0	0	1
	<i>srap</i> [§]	1	1	1	1	1	1	1	7
	Total	3	3	3	4	4	3	3	
Evasion	<i>scpA</i> *	1	1	1	1	1	1	1	7
	<i>sspB</i> *	1	1	1	1	1	1	1	7
	<i>sspA</i> *	1	1	1	1	1	1	1	7
	<i>coa</i> *	0	0	1	0	1	0	0	2
	<i>seb</i> *	0	0	0	1	1	0	0	2
	<i>hla/hly</i> *	1	1	1	1	1	1	1	7
	<i>ψent1</i> [#]	1	1	1	0	1	1	0	5
	<i>ψent2</i> [#]	1	1	1	0	1	1	0	5
	<i>selo</i> [#]	1	1	0	0	0	1	0	3
	<i>seln</i> [#]	1	1	1	0	1	1	0	5
	<i>selm</i> [#]	1	1	1	0	1	1	0	5
	<i>sei</i> [#]	1	1	1	0	1	1	0	5
	<i>seg</i> [#]	1	1	1	0	1	1	0	5
	<i>selv</i> [#]	0	0	0	0	1	0	0	1
	<i>seu</i> [#]	1	1	1	0	1	1	0	5
	<i>sed</i> [#]	0	0	0	0	0	0	0	0
	<i>sej</i> [#]	0	0	0	0	0	0	0	0
	<i>ser</i> [#]	0	0	0	0	0	0	0	0
	<i>ssl8</i> [§]	0	0	1	1	1	0	0	3
	Total	12	12	13	6	15	12	4	
Invasion	<i>hlgA</i> *	1	1	1	1	1	1	1	7
	<i>hlgB</i> *	1	1	1	1	1	1	1	7
	<i>hlgC</i> *	1	1	1	1	1	1	0	6
	<i>hld</i> *	1	1	1	1	1	1	1	7

	<i>lukF-PV*</i>	1	0	1	0	0	0	1	3
	<i>lukS*</i>	1	0	0	0	0	0	1	2
	Total	6	4	5	4	4	4	5	
Total number of virulence genes:		21	19	21	14	23	19	12	

*Virulence genes used by Afzal et al (23)

#Virulence genes associated with ocular *S. aureus* isolates (22)

[§]Virulence genes associated with non-ocular *S. aureus* isolates (22).

STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-6
Objectives	3	State specific objectives, including any prespecified hypotheses	6
Methods			
Study design	4	Present key elements of study design early in the paper	8
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7,8,9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	7,8,9
Bias	9	Describe any efforts to address potential sources of bias	N/A
Study size	10	Explain how the study size was arrived at	N/A (feasibility study)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	N/A
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	N/A
		(c) Explain how missing data were addressed	N/A
		(d) If applicable, describe analytical methods taking account of sampling strategy	N/A
		(e) Describe any sensitivity analyses	N/A
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	11
		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg	11

		demographic, clinical, social) and information on exposures and potential confounders	
		(b) Indicate number of participants with missing data for each variable of interest	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	12-17, tables S1-3 and S6-7 in supplementary data.
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A
		(b) Report category boundaries when continuous variables were categorized	N/A
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A
Discussion			
Key results	18	Summarise key results with reference to study objectives	17-23
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	17-23
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	17-23
Generalisability	21	Discuss the generalisability (external validity) of the study results	17-23
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	23

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.